How big is QuidelOrtho Corp.?

As of Jun 18, QuidelOrtho Corp. has a market capitalization of $1.90 billion, with net sales of $2.77 billion and a net profit of -$333.70 million over the last four quarters. Shareholder's funds are $2.98 billion, and total assets amount to $6.97 billion.

As of Jun 18, QuidelOrtho Corp. has a market capitalization of 1,895.55 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 2,765.50 million, while the sum of net profit for the same period is -333.70 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 2,984.50 million, and total assets amount to 6,967.80 million.

What does QuidelOrtho Corp. do?

QuidelOrtho Corp. develops, manufactures, and markets diagnostic testing solutions in the Pharmaceuticals & Biotechnology industry, with a recent net sales of $694 million and a market cap of approximately $1.9 billion. The company reported a net profit of -$13 million for the most recent quarter.

Overview:<BR>QuidelOrtho Corp. is engaged in the development, manufacturing, and marketing of diagnostic testing solutions within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 694 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,895.55 Million (Small Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.80 <BR>Return on Equity: -2.58% <BR>Price to Book: 0.63 <BR><BR>Contact Details:<BR>Address: 9975 Summers Ridge Road, SAN DIEGO CA: 92121 <BR>Tel: ['1 858 5521100', '1 858 6468023'] <BR>Fax: 1 858 4534338 <BR>Website: http://www.quidel.com/

Should I buy, sell or hold QuidelOrtho Corp.?

Who are in the management team of QuidelOrtho Corp.?

As of March 2022, the management team of QuidelOrtho Corp. includes Dr. Kenneth Buechler (Independent Chairman), Mr. Douglas Bryant (President and CEO), and several independent directors: Ms. Ann Rhoads, Mr. Edward Michael, Ms. Kathy Ordonez, Dr. Mary Polan, and Mr. Charles Slacik, reflecting a diverse leadership structure.

As of March 2022, the management team of QuidelOrtho Corp. includes the following individuals:<BR><BR>- Dr. Kenneth Buechler, who serves as the Independent Chairman of the Board.<BR>- Mr. Douglas Bryant, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Ann Rhoads, who is a Director.<BR>- Mr. Edward Michael, who is an Independent Director.<BR>- Ms. Kathy Ordonez, who is also an Independent Director.<BR>- Dr. Mary Polan, who serves as an Independent Director.<BR>- Mr. Charles Slacik, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executives, highlighting a diverse leadership structure.

Is QuidelOrtho Corp. overvalued or undervalued?

As of February 13, 2024, QuidelOrtho Corp. is considered risky and overvalued due to a negative P/E ratio of -24.49, low ROE of -2.58%, and poor stock performance, with a year-to-date decline of 37.93% compared to a 2.44% gain for the S&P 500.

As of 13 February 2024, the valuation grade for QuidelOrtho Corp. has moved from attractive to risky, indicating a significant shift in the company's financial outlook. The company is currently considered overvalued, especially given its negative P/E ratio and low ROE of -2.58%. Key ratios reveal a Price to Book Value of 0.67, an EV to EBITDA of 8.23, and an EV to Sales of 1.59, which further highlight the company's struggles in generating profits.<BR><BR>In comparison to its peers, QuidelOrtho Corp. has a less favorable EV to EBITDA ratio of 8.04 when compared to Bausch + Lomb Corp., which stands at 14.81. This disparity, along with QuidelOrtho's negative P/E ratio of -24.49, suggests that investors may be pricing in significant risks associated with the company's future performance. Additionally, the company's recent stock performance has lagged behind the S&P 500, with a year-to-date decline of 37.93% compared to a modest gain of 2.44% for the index, reinforcing the notion of an overvalued position.

Is QuidelOrtho Corp. technically bullish or bearish?

As of October 10, 2025, QuidelOrtho Corp. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals on weekly and monthly charts, and has underperformed the S&P 500 with a year-to-date return of -40.94%.

As of 10 October 2025, the technical trend for QuidelOrtho Corp. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating bearishness and the Bollinger Bands showing a bearish signal on both weekly and monthly time frames. Although the MACD and KST are mildly bullish on weekly and monthly charts, the overall sentiment is dampened by the bearish daily indicators. Additionally, QuidelOrtho has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -40.94% compared to the S&P 500's 11.41%.